<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Elvira Mukharryamova on Medium]]></title>
        <description><![CDATA[Stories by Elvira Mukharryamova on Medium]]></description>
        <link>https://medium.com/@elvira.mukharryamova?source=rss-fa9842e88242------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*SOeSzEoQ8lnDvLH4Lyr37Q@2x.jpeg</url>
            <title>Stories by Elvira Mukharryamova on Medium</title>
            <link>https://medium.com/@elvira.mukharryamova?source=rss-fa9842e88242------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 10:27:09 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@elvira.mukharryamova/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Can We Afford the Future of Gene Therapy?]]></title>
            <link>https://medium.com/@elvira.mukharryamova/can-we-afford-the-future-of-gene-therapy-49432b102378?source=rss-fa9842e88242------2</link>
            <guid isPermaLink="false">https://medium.com/p/49432b102378</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[rare-disease]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[gene-therapies]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[Elvira Mukharryamova]]></dc:creator>
            <pubDate>Fri, 07 Aug 2026 02:39:02 GMT</pubDate>
            <atom:updated>2026-08-07T02:39:02.072Z</atom:updated>
            <content:encoded><![CDATA[<h4>Gene therapies are offering real hope to patients with rare genetic diseases, but their multi-million-dollar price tags are raising serious concerns about affordability.</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*tcaDjkOy8C5FfiI1nsmBrw.jpeg" /></figure><p>Every year, thousands of children and adults are diagnosed with rare genetic diseases caused by changes in their DNA. For many of these disorders, there has historically been no cure. Doctors could help manage symptoms and slow the disease progression, but they could not fix the DNA changes that caused it in the first place.</p><p>Gene therapy is beginning to change that.</p><p>By adding, replacing, or modifying genetic instructions inside a patient’s cells, these treatments aim to correct the biological problem driving disease rather than simply managing its consequences.</p><p>For patients living with rare genetic disorders, this represents a remarkable shift in medicine: the possibility of replacing years of treatment and supportive care with a single therapy designed to provide long-lasting, potentially life-changing benefits.</p><p>But this scientific breakthrough comes with a catch: <strong>the price tag.</strong></p><blockquote><strong>Gene therapy showed that we could do something once thought impossible: treat disease at its genetic root. The question now is whether we can afford it.</strong></blockquote><h3>The first multi-million-dollar cure</h3><p><a href="https://www.zolgensma.com/"><strong>Zolgensma</strong></a> was one of the first gene therapies to make the affordability problem impossible to ignore. It was <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease">approved</a> in 2019 to treat paediatric spinal muscular atrophy (SMA), a rare disease caused by the <strong>SMN1</strong> gene, which is missing or not working properly. That gene failure slowly destroys the nerve cells that carry signals from the brain to the muscles. In severe cases, SMA can take away a child’s ability to move, swallow, or even breathe on their own.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*-0PppNx3O-KQnNKg6r24Kg.jpeg" /></figure><p>The wholesale acquisition <a href="http://wholesale acquisition cost of Zolgensma">cost</a> of Zolgensma was <strong>$2.1 million. </strong>It became the most expensive drug in the world.</p><p>The price was unprecedented. But so was the goal.</p><p>Before gene therapy, SMA treatment meant managing the disease: physical therapy, breathing support, medications to slow the decline.</p><p>Zolgensma changed that.</p><p>Instead of treating symptoms for a lifetime, it delivers a working copy of the missing gene in a single infusion. That gives the body the genetic instructions needed to make the survival motor neuron (SMN) protein that keeps nerve cells responsible for muscle movement alive, helping preserve essential muscle function.</p><blockquote><strong>That’s the promise of many gene therapies: a one-time treatment instead of a lifetime of care. It’s also exactly what makes a price like this so hard to solve.</strong></blockquote><h3>Why does a single treatment cost millions?</h3><p>There is little doubt about the transformative impact of gene therapies like Zolgensma on patients. But the question still stands: <strong>why do they cost so much?</strong></p><p>The cost of gene therapies reflects a combination of scientific complexity, manufacturing challenges, and the economics of treating rare diseases.</p><ol><li><strong>The manufacturing problem. </strong>Gene therapies are among the most technically complex medicines ever developed. Many rely on specially engineered viruses that act like delivery vehicles, carrying therapeutic genes into a patient’s cells. Producing them requires specialized cleanrooms, exhaustive quality testing, and a level of precision closer to aerospace engineering than traditional pharmaceutical manufacturing.</li><li><strong>The small-numbers problem. </strong>Unlike many conventional medicines that can be used by millions of people, gene therapies often target extremely rare diseases affecting only a small number of patients. A common medication, such as a blood pressure drug, can spread the cost of research and development across a large population over many years. A gene therapy for a rare condition may only ever be given to hundreds or thousands of patients worldwide. The same years of research, clinical trials, and manufacturing investment must therefore be recovered from a much smaller patient population.</li><li><strong>The value problem.</strong> Another factor is the value these therapies aim to provide. The price of a gene therapy isn’t mainly based on what it costs to manufacture. <strong>It’s based on what it would otherwise cost to treat that disease for a patient’s entire life, things like hospital visits, ongoing therapies, and complications.</strong> So a one-time treatment isn’t priced like a regular drug. It’s priced against everything it’s replacing.</li></ol><h3>Who actually pays for a $2 million treatment?</h3><p>This is where most people get confused.</p><p>A $2 million price tag doesn’t mean a family gets handed a $2 million bill to get the treatment.</p><p>In the U.S., approved gene therapies are typically covered through insurance, employer health plans, or public programs like Medicaid. These organizations essentially pay drug manufacturers on behalf of eligible patients. The cost is absorbed and spread across the healthcare system, not paid directly by the patient <em>(This is a simplified explanation of a much more complex process, one that deserves its own deep dive).</em></p><p>So the real affordability crisis isn’t:</p><blockquote><strong>“Can one family afford a $2 million treatment?”</strong></blockquote><p>It’s:</p><blockquote><strong>“Can healthcare systems sustainably absorb a growing number of one-time, multi-million-dollar treatments?”</strong></blockquote><p>One expensive therapy is a manageable outlier. A pipeline of dozens of them, each serving small patient populations but each carrying a seven-figure price, is a structural problem nobody has solved.</p><h3>The payment model problem</h3><p>So why can’t a system built to handle thousands of expensive treatments over time, absorb a pipeline of expensive one-time treatments now?</p><p><strong>Because that system was never built to pay for treatments like this.</strong></p><p>Most healthcare spending was designed around chronic illness, conditions that people manage for years with small, repeated costs like a monthly prescription or regular doctor visits. That kind of spending is predictable, so it’s easy for insurers and health systems to plan and budget for.</p><p>Gene therapy flips that completely. Instead of small payments spread out over years, it’s one enormous payment, made all at once, for a benefit that’s supposed to last a lifetime, though even that’s not fully proven yet. <strong>Most gene therapies are too new for anyone to know for certain how long their effects will actually hold up.</strong></p><p>This mismatch between pricing logic and healthcare budgeting has already created challenges for gene therapies reaching patients.</p><p><strong>Pfizer’s Beqvez</strong>, a gene therapy for hemophilia B, got <a href="https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-beqveztm-fidanacogene-elaparvovec">approved</a> and worked as intended, but it never took off commercially, and Pfizer eventually <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-it-will-end-global-development-gene-therapy-beqvez-nikkei-reports-2025-02-20/">stopped</a> selling it. The issue wasn’t whether the therapy worked. It was whether the healthcare system, physicians, and patients were ready to pay for something with such a different cost structure.</p><blockquote><strong>That’s the real lesson: a treatment can succeed in the lab and still fail simply because of how healthcare is set up to pay for things.</strong></blockquote><h3>Building a system that can actually pay for cures</h3><p>For the first time, medicine is facing a challenge created not by a lack of scientific possibility, but by its own success. We have learned how to change the course of some diseases. Now, we must build a system capable of making those breakthroughs accessible to the people who need them.</p><p>The solution is unlikely to just be a simple price drop. It will require rethinking how healthcare pays for medicine itself. New pricing models, from paying over time in smaller instalments to linking payment to whether treatments deliver lasting benefits, are already being <a href="https://www.cms.gov/newsroom/press-releases/cms-expands-access-lifesaving-gene-therapies-through-innovative-state-agreements">tested</a>. We are building, piece by piece, the financial infrastructure needed for an era of medicine where cures arrive as a single treatment rather than years of care.</p><p>That is what makes this field so exciting to follow: not only the science that creates these breakthroughs, but the challenge of turning them into treatments that truly reach patients.</p><p><em>Thanks for reading my article. A bit about me: my background is in medical genomics, and I’ve become increasingly interested in gene therapy market access and reimbursement. Understanding how these therapies get priced, financed, and actually reach, or fail to reach, patients matters just as much as understanding the science behind them.</em></p><p><em>This is the first in a series looking honestly at where gene therapy delivers on its promise, and where the system around it still has to catch up. Follow along as I try to unpack the complex, often overlooked themes shaping the future of gene therapy.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=49432b102378" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>